Compare Ascendis Pharma A/S (ASND) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Boston Beer Company Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Boston Beer Company Inc trades at $176.79 (market cap $1.84B). The key difference: Ascendis Pharma A/S is far larger — about 9.6× Boston Beer Company Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| ASND | SAM | |
|---|---|---|
Market Cap | $17.74B | $1.84B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $260.05 |
52-Week Low | $163.32 | $161.08 |
Enterprise Value | $18.11B | $1.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SAM trades at $176.79, up 1.1% on the day, amid a bearish technical signal but with a consensus analyst price target of $222.67 suggesting upside. Recent earnings show volatility with a Q1 2026 miss, while full-year 2025 net income improved to $108.47M. Cash flow remains positive, but 2026 revenue and profit projections indicate challenges. The company is investing in brand innovation and Beyond Beer expansion to drive growth.
The outlook is mixed; valuation ratios appear reasonable, and strategic initiatives support long-term potential, but near-term volume pressure and negative 2026 profit forecasts pose risks. Investor sentiment is cautious, with most analysts rating Hold. Key catalysts include execution on cost savings and brand momentum against a competitive backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
